Cardiac Troponin I Concentration May Predict Mortality

THURSDAY, Aug. 10, 2023 (HealthDay News) -- Cardiac troponin I (cTnI) concentration is associated with medium-term mortality in an unselected hospital population, according to a study published online Aug. 7 in Heart.
Jonathan Hinton, from the University of Southampton in the United Kingdom, and colleagues conducted a prospective observational study including 20,000 consecutive in-hospital and outpatient patients who had a blood test for any reason at a large teaching hospital and in whom a high-sensitivity cTnI assay was measured.
Overall, 91.4 percent of the patients did not have a clinical indication for cTnI testing. The researchers found that 14.1 percent of patients died at a median of 809 days. If the cTnI concentration was above the upper limit of normal, mortality was significantly higher (45.3 versus 12.3 percent). In a multivariable analysis, log10 cTnI concentration was independently associated with mortality (hazard ratio, 1.76). The relationship persisted in a landmark analysis, excluding deaths within 30 days.
"These findings suggest that a snapshot cTn in a hospital population may represent a biomarker of overall medium-term mortality," the authors write.
One author disclosed ties to the biopharmaceutical industry.
Related Posts
Abbott reabrirá su planta de fórmula infantil el 4 de junio
MIÉRCOLES, 25 de mayo de 2022 (HealthDay News) -- A partir del 4 de junio,...
Prior COVID Infection Doesn’t Guarantee Good Immunity: Study
TUESDAY, Aug. 31, 2021 (HealthDay News) -- You caught a case of COVID-19 and...
More Diverse Pool of Blood Donors Needed to Help Sickle Cell Patients
TUESDAY, Sept. 6, 2022 (HealthDay News) -- A network that receives and supplies...
Vietnamese Pangolins Carry COVID-Like Coronavirus
FRIDAY, March 11, 2022 (HealthDay News) -- In a finding that suggests the new...
